Dr. Jose Lutzky, MD

Dr. Lutzky practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Lutzky's NPI, 1235127929, was assigned on October 7, 2005. Dr. Lutzky graduated from Federal University of Rio Grande do Sul School of Medicine in 1980. Dr. Lutzky holds Florida license ME43799.

Dr. Lutzky's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Lutzky's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Lutzky to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lutzky practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Lutzky's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Lutzky is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Lutzky's licenses on file in 2 states: Florida and California.

Dmand AI lists chronic leukemia, lung cancer, lymphoma and prostate cancer among the conditions Dr. Lutzky treats.

CMS data shows 697 Medicare services from Dr. Lutzky across 3 procedure codes in 2024, for 180 Medicare patients. Medicare paid $35,430 for them.

CMS counts 180 Medicare patients who saw Dr. Lutzky in 2024. The largest group is 75 to 84, with 86 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lutzky's median patient age at 76, with 36% women.

In 2024, Dr. Lutzky wrote 306 Medicare Part D claims for 69 patients. 46% of them were for generic drugs. CMS names the drug for 226 of them, across 6 drugs with 11 or more claims each, at $1,322,139 in total drug cost. In 2023, CMS named 190 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Lutzky for performance year 2024, reported as part of a group. Dr. Lutzky accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lutzky as offering telehealth.

Dmand AI links 70 papers to Dr. Lutzky, published from 2008 to 2024. 2018 was the busiest year, with 6. The most frequent topics are Melanoma, Skin Neoplasms and Antineoplastic Combined Chemotherapy Protocols. Dr. Lutzky has published most often in J Immunother Cancer. Dr. Lutzky's most frequent co-authors are Richard D. Carvajal, MD, Thomas F. Gajewski and Anna C. Pavlick, DO.

Dmand AI links Dr. Lutzky to 29 clinical trials, 18 of them phase 2 studies. 11 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Uveal Melanoma. National Cancer Institute (NCI) sponsors the most, 11. Open Payments lists research payments to Dr. Lutzky that name 1 trial.

CMS Open Payments shows 1,052 general payments to Dr. Lutzky from 52 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 78% of the total. TriSalus Life Sciences, Inc. paid the most, $205,164. It also lists 1 research payment totaling $998 in 2016, naming 1 clinical trial.

Dmand AI lists 4 awards for Dr. Lutzky, most recently America's Top Doctors in 2020.

Dr. Lutzky graduated from Federal University of Rio Grande do Sul School of Medicine in 1980. Dr. Lutzky is a member of ASCO.

Dr. Lutzky is in network with 12 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.